LEIDEN, The Netherlands, December 11, 2025 / Biotech Newswire / --

荷兰莱顿，2025年12月11日 /生物技术新闻社/ --

ProteoNic BV

普罗特奥尼克有限公司

, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic® technology has been licensed by Ginkgo Bioworks (NYSE: DNA) for use in a project awarded to Ginkgo by the Biomedical Advanced Research and Development Authority (BARDA).

，一家为生物制药和病毒载体生产提供高端矢量技术的领先供应商，今天宣布其专有的2G UNic®技术已被Ginkgo Bioworks（纽约证券交易所代码：DNA）授权使用，用于生物医学高级研究与开发局（BARDA）授予Ginkgo的一个项目。

The project, funded through BARDA’s Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), aims to develop innovations that strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies (mAbs) to treat infection by filoviruses, such as Ebola (EBOV) and Sudan Virus (SUDV)..

该项目由BARDA的生物制药生产准备联盟（BioMaP联盟）资助，旨在开发创新技术，以增强国内单克隆抗体（mAbs）的生产能力并降低成本，用于治疗由丝状病毒（如埃博拉病毒（EBOV）和苏丹病毒（SUDV））引起的感染。

The project, with a total value of up to $22.2 million, brings together a team led by Ginkgo Bioworks that includes Advanced BioScience Laboratories (ABL), Isolere Bio by  Donaldson, NeuImmune, and ProteoNic. Collectively, the project team will develop and integrate innovative technologies spanning the full mAb production process, from cell line development through purification, to create a more rapid, scalable, and cost-effective biomanufacturing solution for critical medical countermeasures..

该项目总价值高达 2220 万美元，由 Ginkgo Bioworks 领导的团队汇集了高级生物科学实验室 (ABL)、Donaldson 旗下的 Isolere Bio、NeuImmune 和 ProteoNic。该团队将共同开发并整合覆盖单克隆抗体（mAb）全生产流程的创新技术——从细胞系开发到纯化，为关键医疗对策提供更快速、可扩展且更具成本效益的生物制造解决方案。

ProteoNic’s contribution focuses on the application of its proprietary

ProteoNic 的贡献集中在应用其专有的

2G UNic vector and transposon technologies

2G UNic载体和转座子技术

, designed to maximize expression and productivity in mammalian systems. By integrating these tools into the mAb production platform, ProteoNic aims to significantly enhance manufacturing efficiency and yield, reducing both time and cost for large-scale bioproduction.

，旨在最大化哺乳动物系统中的表达和生产力。通过将这些工具整合到单克隆抗体生产平台中，ProteoNic 旨在显著提高生产效率和产量，同时减少大规模生物生产的成本和时间。

“We are proud that Ginkgo has chosen to license and apply our 2G UNic in this important initiative,”

“我们很自豪银杏选择授权并将我们的2G UNic应用到这一重要计划中，”

said Frank Pieper, CEO of ProteoNic.

普罗特奥尼克公司首席执行官弗兰克·皮珀说。

“Our 2G UNic technology has consistently demonstrated substantial improvements in protein expression and manufacturing productivity. Contributing this capability to a project of such public health importance aligns perfectly with our mission to enable more efficient, accessible biologics production globally.”.

“我们的2G UNic技术始终在蛋白质表达和生产效率方面表现出显著的提升。将这一能力贡献给如此重要的公共卫生项目，完全符合我们促进全球更高效、更易获得的生物制品生产的使命。”

This collaboration underscores ProteoNic’s continued expansion into next-generation biologics manufacturing, supporting applications in both therapeutic protein production and cell and gene therapy. By enabling higher productivity from existing manufacturing infrastructure, ProteoNic’s technology provides a sustainable path to strengthening biomanufacturing resilience in response to future global health threats..

此次合作突显了ProteoNic在下一代生物制品制造领域的持续扩展，支持治疗性蛋白质生产和细胞与基因治疗的应用。通过提高现有制造基础设施的生产力，ProteoNic的技术为增强生物制造的韧性提供了一条可持续的路径，以应对未来的全球健康威胁。

This project has been awarded through the BioMaP-Consortium, a consortium overseen by BARDA and managed by Advanced Technology International (ATI), and funded in whole or in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); BARDA, under Other Transaction (OT) number #75A50123D00003..

该项目已通过BioMaP联盟授予，该联盟由BARDA监督，并由先进技术国际（ATI）管理，全部或部分由美国卫生与公众服务部（HHS）、战略准备与响应管理局（ASPR）、BARDA提供的联邦资金资助，其他交易（OT）编号为#75A50123D00003。

Semantic keywords: Hemorrhagic Fever, Ebola, Antibodies, Monoclonal, Cell Line, Ebolavirus, Recombinant Proteins, Cloning, Molecular, Genetic Vectors, Biological Products, Biotechnology, Technology, Netherlands, ProteoNic, 2G UNic, Ginkgo Bioworks, BARDA, BioMaP-Consortium, monoclonal antibodies, anti-filovirus therapies, Ebola, Sudan Virus, biomanufacturing, vector technology, viral vector production, biopharmaceutical production, Advanced BioScience Laboratories, Isolere Bio, NeuImmune, cell line development, purification, mAb production, transposon technologies, mammalian expression systems, protein expression, manufacturing productivity, public health preparedness, therapeutic protein production, global health threats.

语义关键词：出血热、埃博拉、抗体、单克隆、细胞系、埃博拉病毒、重组蛋白、克隆、分子、基因载体、生物制品、生物技术、技术、荷兰、ProteoNic、2G UNic、银杏生物工程、BARDA、BioMaP联盟、单克隆抗体、抗丝状病毒疗法、埃博拉、苏丹病毒、生物制造、载体技术、病毒载体生产、生物制药生产、先进生物科学实验室、Isolere Bio、NeuImmune、细胞系开发、纯化、单克隆抗体生产、转座子技术、哺乳动物表达系统、蛋白质表达、生产效率、公共卫生准备、治疗性蛋白生产、全球健康威胁。

About

关于

ProteoNic

普罗特奥尼克

ProteoNic is a privately held company dedicated to delivering premium vector and transposon technology for biologics manufacturing. Its proprietary 2G UNic technology provides leading solutions for improving gene expression in mammalian production systems. ProteoNic licenses its technology to biopharmaceutical companies and CDMOs globally for use in therapeutic protein  and gene therapy applications..

ProteoNic是一家私营公司，致力于为生物制品制造提供优质的载体和转座子技术。其专有的2G UNic技术为提高哺乳动物生产系统中的基因表达提供了领先的解决方案。ProteoNic将其技术授权给全球的生物制药公司和合同开发与生产组织（CDMO），用于治疗性蛋白质和基因治疗应用。

Contact

联系

ProteoNic

普罗特欧尼克

Jonathan Frampton

乔纳森·弗兰普顿

VP Business Development

商务发展副总裁

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Source: Biotech Newswire

来源：生物技术新闻社